The cholesterol-lowering agents known as statins have in vitro activities against human pathogenic fungi, such as Candida species, Cryptococcus neoformans, and Zygomycetes. Synergy between statins and azoles against these fungi has also been reported. We evaluated the in vitro activities of two statins, lovastatin and simvastatin, alone and in combination with azoles and amphotericin B, against clinical isolates of Aspergillus spp. A disk diffusion assay showed that both statins were active against Aspergillus spp. The minimal inhibitory concentration (MIC) ranges for lovastatin and simvastatin against Aspergillus spp. were 16 to 256 mg/ ml and 4 to 256 mg/ml, respectively. Although both statins were fungicidal for A. fumigatus, the MICs were vastly higher than clinically achievable concentrations. The results of a combined agar dilutionÁEpsilometer test as well as a disk diffusion assay showed that neither statin had any effect on the in vitro activities of itraconazole, voriconazole, or amphotericin B against Aspergillus spp.
Introduction
Invasive aspergillosis (IA) has emerged as a leading cause of death in immunocompromised patients [1] and the most common etiologic agent of IA is Aspergillus fumigatus. Although several antifungal agents, such as amphotericin B, itraconazole, and caspofungin acetate, are now being used in the prophylaxis and treatment of IA, the number of deaths due to IA remains high [1] . Also of concern is the fact that clinical isolates of nonfumigatus Aspergillus species and even itraconazoleresistant A. fumigatus are being reported in cases of IA with increasing frequency [2Á4]. Therefore, novel and effective prophylactic and therapeutic approaches to improve the prognosis of IA are needed.
Statins are cholesterol-lowering agents that act by inhibiting 3-hydroxy-3-methylglutaryl-coenzyme A reductase, a rate-limiting enzyme in the cholesterol biosynthetic pathway [5] . Statins have in vitro activities against several human pathogenic fungi, including Candida spp., Cryptococcus neoformans, and Zygomycetes [6Á8]. In a recent study, Macreadie et al. reported that two statins, atorvastatin and simvastatin, inhibited the growth of one isolate of A. fumigatus [9] . Moreover, statins have been found to exhibit synergistic interactions with azoles against Saccharomyces cerevisiae [6] , Candida spp. isolates, including fluconazole-resistant Candida [7] , and Zygomycetes isolates [8] .
In this study, we assessed the antifungal activities of simvastatin and lovastatin, the latter has not been evaluated previously, against A. fumigatus by using three independent antifungal susceptibility testing methods. We also extended the tests to include itraconazole-resistant A. fumigatus strains, as well as A. flavus, A. terreus, and A. niger strains, which are increasingly encountered causes of IA. Finally, we evaluated the in vitro interaction of the statins with itraconazole, voriconazole, and amphotericin B against Aspergillus species.
Materials and methods

Fungal strains
The strains used in this study (nine A. fumigatus, one A. flavus, one A. terreus, and one A. niger) were all isolated from patients with IA diagnosed and treated at the Peking University First Hospital and were stored at the Research Center for Medical Mycology, Peking University (Table 1) . A. fumigatus strains AF2 and AF6 were itraconazole-resistant strains isolated from one patient [4] . The Clinical and Laboratory Standards Institute quality control strain Candida parapsilosis ATCC22019 [10] was included in all assays. All Aspergillus spp. cultures were grown on yeast agar glucose media (2% glucose, 0.5% yeast extract, 2% agar, trace elements, and vitamin mixture) [11] at 378C for 4 days, and were harvested with saline water containing 0.2% Tween 20.
Pharmacologic agents
Lovastatin and simvastatin (Calbiochem, La Jolla, CA; stock solution concentration, 4 mg/ml) were hydrolyzed in active open acid form using ethanolic sodium hydroxide (15% [v/v] ethanol and 0.25% [w/v] sodium hydroxide) at 608 C for 2 h) as described elsewhere [8] . Stock solutions of lovastatin and simvastatin were filter sterilized and stored in the dark at (208 C. Stock solutions (1.6 mg/ml) of itraconazole (Xian-Janssen Pharmaceutical Ltd., Xi'an, China), voriconazole (Pfizer, Hong Kong, China), and amphotericin B (Sigma, St. Louis, MO) were prepared in 100% dimethyl sulfoxide.
Disk diffusion assay
After growth and harvesting of the fungal strains, a 200 ml suspension (1 )10 6 conidia/ml) of each of the tested strains was spread uniformly onto yeast agar glucose plates. Blank paper disks 6-mm in diameter were impregnated with 20 mg lovastatin or simvastatin. After the disks were allowed to dry, they were placed onto the center of the inoculated agar plates. The plates were incubated at 358C, and the diameters of the zones of inhibition were measured at 24 h and 48 h.
Each assay was performed in triplicate on three different days, and the mean diameters9standard deviations were reported.
Broth microdilution assay
The broth microdilution assay was performed according to the Clinical and Laboratory Standards Institute M38-A reference method [10] . Briefly, fungal susceptibility was determined in RPMI 1640 agar plates (Sigma) buffered to pH 7.0 using 3-(N-morpholino) propanesulfonic acid (MOPS) (Sigma). The statins were tested in a concentration range of 256Á0.5 mg/ml. Conidial suspensions of all the fungal strains were adjusted to a final concentration of about 2 )10 4 Table 1 Diameters of the zone of growth inhibition (in mm) produced by lovastatin and simvastatin in Aspergillus spp. by the disk diffusion assay (mean9standard deviation, mm).
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Lovastatin 
Minimum fungicidal concentration assays
The minimum fungicidal concentrations (MFC) were determined as described previously [12] . Briefly, after the MIC for each strain was determined, the microtiter plates were shaken and 20 ml suspensions from each well showing complete inhibition of growth (100%) and from the growth control well were subcultured onto Sabouraud dextrose agar plates. The MFC was defined as the lowest drug concentration at which fewer than three fungal colonies were observed after 48 h of incubation at 358C. The MFC value represents the concentration at which approximately 99.9% of the original inoculum is killed. The MFC determinations were done in triplicate on 3 different days, and the geometric mean values were reported.
Interaction of statins with itraconazole, voriconazole, and amphotericin B
To determine whether statins combined with itraconazole, voriconazole, or amphotericin B had interactive effects on Aspergillus spp., we used two methods; combining the agar dilution and the Epsilometer test (Etest; AB Biodisk, Solna, Sweden) as described previously [8] , and using the disk diffusion assay. Etest susceptibility testing of itraconazole, voriconazole, and amphotericin B was performed in RPMI 1640 (Sigma) plates containing a non-inhibitory concentration of lovastatin (30 mg/ml or 0.5 mg/ml) or simvastatin (30 mg/ml or 0.5 mg/ml) or no statin as control. We chose the 30 mg/ml concentration because it is achievable with therapeutic doses of the statins and the 0.5 mg/ml concentration because it is achievable in both animal models and humans [13] . The plates were incubated at 358C for 48 h, and the MICs were recorded. For the disk diffusion assay, 3 mg of itraconazole, 3 mg of voriconazole, or 30 mg of amphotericin B was combined with 5 mg of one of the statins. The combinations were placed on the disks, which were then placed onto the center of agar-containing plates that had been inoculated as described above; 3 mg of itraconazole, 3 mg of voriconazole, and 30 mg of amphotericin B alone were placed on disks and tested as controls. Disks statins were used as controls. All the plates were incubated at 358C for 48 h.
Results
Both lovastatin and simvastatin inhibited the growth of these Aspergillus spp. The initial disk diffusion assay results showed that lovastatin and simvastatin produced zones of growth inhibition against the A. fumigatus isolates at 24 h and 48 h of incubation, demonstrating the inherent activities of both statins against these Aspergillus spp. (Fig. 1) . The diameters of the zones of growth inhibition are shown in Table 1 .
Both statins also inhibited the growth of the itraconazole-resistant A. fumigatus strains AF2 and AF6. However, we noted the diameters of the inhibition zones of the statins for the itraconazole-resistant A. fumigatus strains were smaller than those for the itraconazole-susceptible strains (Fig. 1, Table 1 ).
The susceptibility of the non-A. fumigatus Aspergillus strains to the statins was less than that found with A. fumigatus. The results of the disk diffusion assay showed that 20 mg of each statin inhibited growth of A. flavus, A. terreus, and A. niger at 24 h but lost all antifungal activities by 48 h (data not shown). Zones of growth inhibition against A. flavus and A. terreus (but not A. niger) were produced when the statin dose was increased to 200 mg (Table 1) .
To quantify the Aspergillus species' susceptibilities to the statins, we determined the agents' MICs. The MICs of the two statins to the Aspergillus spp. were high (4 to 256 mg/ml), vastly exceeding the plasma concentrations of the drugs achieved in clinical trials (10Á40 ng/ ml) [13] . Similarly, a previous study found that the concentration of the statins needed to inhibit A. fumigatus growth was much higher than the therapeutic concentration (10 mM or 58 mg/ml for atorvastatin, 1 mM or 0.4 mg/ml for simvastatin) [9] .
Discussion
In the present study, we found that lovastatin and simvastatin can inhibit growth of Aspergillus spp., which is consistent with that of a previous study showing that atorvastatin and simvastatin inhibited the growth of one A. fumigatus isolate [9] . The MICs of the two statins to the Aspergillus spp., however, were extremely high (4 to 256 mg/ml), exceeding the plasma concentrations of the drugs achievable in clinical doses used for treating hyperlipoidemia.
As previously described, statins at high concentrations have synergistic activity with azoles against Saccharomyces cerevisiae, Candida species, Cryptococcus neoformans, and Zygomycetes [6Á8, 14] . However, the concentrations of statins that exhibited synergy between azoles and statins were so high that they cannot be achieved in the human plasma. In this study, although we chose statin concentrations achieved with therapeutic doses and in animal models and humans, no synergy was observed between the statins and azoles against Aspergillus spp. (data not shown). This finding is consistent with the previous observation that statins at lower concentrations had no positive interactions with azoles against Candida albicans [15] . In addition, the statins used in this study did not show any effect on the antifungal activities of amphotericin B against Aspergillus species (data not shown). In summary, at clinically achievable concentrations, lovastatin and simvastatin have no activity against Aspergillus spp., although they do when their concentrations are increased to a very high level, which would be toxic to human cells. Moreover, at clinically achievable concentrations, these statins have no effect on the in vitro activities of itraconazole, voriconazole, or amphotericin B against the Aspergillus spp.
